Skip to main content

Table 1 Demographics of patients and tumors

From: Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas

Case

Age (years old)

M/F

Tumor

Bev (cycles)

Lesion

Location

Radiotherapy

Bev from RT (month)

Reduction Rate

Outcome

FLAIR ( %)

Gd ( %)

Radiological

Clinical

Case 1

70

F

anaplastic

4

Tumor 1 (non-irradiated)

R frontal (cranial)

 

N/A

−71

198

Progression

Improved L hemiparesis

Tumor 2 (non-irradiated)

R frontal (caudal)

 

N/A

126

Progression

Tumor 3

R frontal

SRT 32Gy

8

−89

Response

Tumor 4

R frontotemporal

SRS 23Gy/SRS 20Gy/ SRS 22Gy/ SRT 33Gy

3

7

Stable

Case 2

52

M

anaplastic

3

Tumor 5

occipital

SRS 14Gy/ SRS 14Gy/ SRT 25.5Gy/BNCT

13

−47

−10

Stable

Unchanged dizziness and visual disturbance

Tumor 6

L temporal

SRT 27Gy

20

−79

Response

Tumor 7 (non-irradiated)

R temporal

 

N/A

−5

Stable

Tumor 8

L tentorial edge

SRS 20Gy

2.5

−55

Response

Case 3

76

F

atypical

6

Tumor 9

parasagittal

SRT 24Gy/ BNCT

8

−29

0

Stable

Unchanged L hemiparesis

Case 4

52

M

grade I

3

Tumor 10

petroclival

GKR 14Gy/RT 30Gy/GKR 14Gy

5.5

−33

−14

Stable

Improved R hemiparesis and L ataxia

Case 5

69

F

grade I

3

Tumor 11

parasagittal

SRS/ SRS

13

−90

−47

Stable

Improved gait disturbance

Case 6

46

F

anaplastic

6

Tumor 12

frontal base

EBRT 60Gy/ BNCT/BNCT

4

−45

−48

Stable

Unchanged cognitive dysfunction

Tumor 13

orbit

BNCT/BNCT

4

−65

Respose

Tumor 14

infratemporal

BNCT/BNCT

4

12

Stable

Tumor 15

frontal convexity

EBRT 60Gy/ BNCT/BNCT

4

19

Stable